Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Forge Announces Visible Gold & Continued Porphyry Mineralization at Alotta Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Filament Health Corp N.FH


Primary Symbol: FLHLF

Technology Scientific & Technical Instruments
Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of Psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral delivery (1mg and 25mg), PEX020 Psilocin - oral delivery (dose withheld), and PEX030 Psilocin - sublingual delivery (dose withheld). The Company's preclinical stage drug candidates include AEX010 Ayahuasca - oral delivery (dose withheld), and AEX020 Monoamine Oxidase Inhibitor - oral delivery (dose withheld). The Company’s internal drug discovery and development program is carried out by its wholly owned subsidiary, Psilo Scientific Ltd., and is focused on developing standardized pharmaceutical-grade drug candidates from botanical psychedelic biomass.


GREY:FLHLF - Post by User

Filament Health Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1601)
•••
  • lscfaX
Comment by lscfaon Aug 15, 2023 11:23am
196 Views
Post# 35589047

RE:1-for-10 rollback

RE:1-for-10 rollbackJupiter has $217 mil Cdn cash & securities but assuming 90% redemptions and $13.3 mil transaction costs so only $7 mil cdn cash after RTO and total of 29.3 mil shs o/s
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities